Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease

Phase 2

Recruiting

Conditions: Alzheimer Disease

Registration Number: NCT06570928

Lead Sponsor: Federal University of Latin American Integration

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 72

Inclusion Criteria

Inclusion Criteria: - Be over 60 years old; - Have been diagnosed with AD at least 1 year ago; - Present mild to moderate symptoms of AD. Exclusion Criteria: - Have a diagnosis of other dementias or factors correlated; - Present psychosis or first-degree relatives with a history from psychosis, schizophrenia, epilepsy; - Individuals with a history of psychoactive substance abuse will be included in the study; - Present severe symptoms of AD.

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mini Mental State Exam (MMSE)

Secondary Outcome Measures

Name	Time	Method
BDNF (Brain Derived Neurotrophic Factor);Inflammatory markers: TNFa (Tumor Necrosis Factor alpha), IL-6 (Interleukin-6), IL-1ß (Interleukin-1 beta), and IL-10 (Interleukin-10);Neuropsychiatric Inventory-Questionnaire (NPI-Q);Geriatric Depression Scale (GDS);Quality of Life in Alzheimer's Disease scale (QoL-AD);Cornell Scale for Depression in Dementia (CSDD);Epworth Sleepiness Scale (ESS );Specific markers of Alzheimer's disease: Beta-amyloid 40, beta-amyloid 42, tau protein (fraction 181), and phosphorylated tau protein